After his medical residency at Massachusetts General Hospital in Boston and heme/onc fellowship at Memorial Sloan Kettering Cancer Center, he joined the Adult Bone Marrow Transplantation Service of MSKCC where he serves as an Assistant Attending. He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.
Graft-versus-Host Disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation which is driven by host antigens that elicit polyclonal responses by donor T cells. The donor T cell pool begins with an immensely diverse population of naive T cells, each with a unique rearranged T cell receptor (TCR) poised to recognize an appropriately presented antigen. How some of these T cells clones are selectively expanded to initiate the devastating alloreaction is poorly understood. Next-generation sequencing offers an unprecedented opportunity to evaluate, in an unbiased fashion, the dynamics of T cell populations as they cause GVHD, as well as during graft-versus-tumor reactions. I am characterizing the T Cell Receptors in mouse models of GVHD by deep sequencing.
Massachusetts General Hospital Patient Safety Star Award, 2012.
Alpha Omega Alpha, September 2009.
Community Service Award, Medical Society of the State of New York, June 2010.
Travel Award, American Society of Hematology, Annual Meeting, December 2005
Jonathan Peled is supported by a T32 Institutional Training Grant (Academic Year 2014-2015).